Symbols

LQDA

Liquidia·NASDAQ

--(--)

LQDA fundamentals

LQDA Q4 2025 Earnings

Liquidia (LQDA) released its earnings on Mar 5, 2026: revenue was 92.02M (YoY +3055.73%), missed estimates; EPS was 0.15 (YoY +133.33%), missed estimates.

Revenue / YoY

92.02M

+3055.73%

EPS / YoY

0.15

+133.33%

Report date

Mar 5, 2026

LQDA Earnings Call Summary for Q4,2025

Revenue Growth: $148.3M in 2025 net product sales, up 74% YoY in Q4.
Patient Momentum: 2,900+ patients shipped, 85%+ conversion rate, 860 prescribers.
Market Leadership: 17% Q4 2025 inhaled treprostinil share, outpacing competitor SMI.
Financial Strength: $190.7M cash, $33M Q4 cash flow, $14.6M net income.
Pipeline Ambition: L-606 study launch, $1B+ 2027 target, expanding into PH-COPD and systemic sclerosis.

Earnings

EPS

Revenue

Revenue & Expenses

LQDA has released its 2025 Q4 earnings report, with revenue of 92.02M, reflecting a YoY change of 3054.65%, and net profit of 14.55M, showing a YoY change of 137.80%. The Sankey diagram below clearly presents LQDA's revenue sources and cost distribution.

Key Indicators

Liquidia (LQDA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Liquidia (LQDA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Liquidia (LQDA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Liquidia (LQDA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown